StreetInsider.com News Articles

RBC Capital on Roche Holding (ROG:SW) (RHHBY): 'Strong momentum into 3Q26 could make for a tricky set-up'

Mon, 19 Oct 2026 09:31:07 -0400

RBC Capital analyst Trung Huynh reiterated an Outperform rating and CHF400.00 price target on Roche Holding (ROG:SW) (OTC: RHHBY).

The analyst commetned: "Strong momentum into 3Q26 could make for a tricky set-up; We are ahead of consensus on the top-line (+2.7%) driven by broad-based Pharma strength (+1.9%), with Hemlibra (+5%), Polivy (+4%), and Alecensa (+4%) leading upside, complemented by Diagnostics (+1%). However, if numbers are in line, it may make for a tricky quarter given the stock is close to all-time highs. The key investor debate remains around giredestrant launch, mgmt has cautioned sampling could weigh on firstyear sales and competitor

RBC Capital on Roche Holding (ROG:SW) (RHHBY): 'Strong momentum into 3Q26 could make for a tricky set-up'

Mon, 19 Oct 2026 09:31:07 -0400

RBC Capital analyst Trung Huynh reiterated an Outperform rating and CHF400.00 price target on Roche Holding (ROG:SW) (OTC: RHHBY).

RBC Capital on Roche Holding (ROG:SW) (RHHBY): 'Strong momentum into 3Q26 could make for a tricky set-up'

Mon, 19 Oct 2026 09:31:07 -0400

RBC Capital analyst Trung Huynh reiterated an Outperform rating and CHF400.00 price target on Roche Holding (ROG:SW) (OTC: RHHBY).

RBC Capital on Roche Holding (ROG:SW) (RHHBY): 'Strong momentum into 3Q26 could make for a tricky set-up'

Mon, 19 Oct 2026 09:31:07 -0400

RBC Capital analyst Trung Huynh reiterated an Outperform rating and CHF400.00 price target on Roche Holding (ROG:SW) (OTC: RHHBY).

Genentech to Present Pivotal Data at ESMO 2026, Showcasing Advances Across Its Lung and Breast Cancer Late-Stage Portfolio

Mon, 19 Oct 2026 01:00:00 -0400

Phase III Krascendo 1 results demonstrated divarasib’s superiority over current standard of care, first-generation KRAS G12C inhibitors, in previously treated advanced G12C-mutated non-small cell lung cancer
Patient-reported outcomes from Phase III lidERA study showed improved efficacy of giredestrant over standard endocrine therapy is achieved without compromising tolerability and health-related quality of life in early-stage breast cancer
Second Phase III results in Chinese patients with metastatic nasopharyngeal carcinoma demonstrate the potential of Tam-Peli, a next-generation B7-H3 targeted ADC, to deliver robust efficacy with a favorable safety profile in high-unmet-need solid tumors

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Genentech, a member of

Genentech to Present Pivotal Data at ESMO 2026, Showcasing Advances Across Its Lung and Breast Cancer Late-Stage Portfolio

Mon, 19 Oct 2026 01:00:00 -0400

Phase III Krascendo 1 results demonstrated divarasib’s superiority over current standard of care, first-generation KRAS G12C inhibitors, in previously treated advanced G12C-mutated non-small cell lung cancer
Patient-reported outcomes from Phase III lidERA study showed improved efficacy of giredestrant over standard endocrine therapy is achieved without compromising tolerability and health-related quality of life in early-stage breast cancer
Second Phase III results in Chinese patients with metastatic nasopharyngeal carcinoma demonstrate the potential of Tam-Peli, a next-generation B7-H3 targeted ADC, to deliver robust efficacy with a favorable safety profile in high-unmet-need solid tumors

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Genentech, a member of

FDA approves Genentech's Enspryng for thyroid eye disease

Fri, 16 Oct 2026 01:00:25 -0400

Genentech, a member of the Roche Group (SIX: RO, ROP; OTCQX: RHHBY), said the U.S. Food and Drug Administration has approved Enspryng (satralizumab-mwge) for the treatment of adults with thyroid eye disease (TED), making it the first subcutaneous treatment option for the condition that can be self-administered at home.

The approval, which followed a priority review designation, is based on data from the Phase III SatraGO-1 and SatraGO-2 studies, which together enrolled 258 patients across 19 countries. While SatraGO-1 did not meet its pre-specified primary efficacy endpoint at week 24, SatraGO-2 showed a proptosis response rate of 52.9% in the Enspryng

FDA approves Genentech's Enspryng for thyroid eye disease

Fri, 16 Oct 2026 01:00:25 -0400

FDA Approves Genentech’s Enspryng, a First-in-Class IL-6R Inhibitor, as the First and Only At-Home Subcutaneous Treatment Option for Thyroid Eye Disease (TED)

Fri, 16 Oct 2026 01:00:00 -0400

FDA approval based on Phase III SatraGO-1 and -2 studies, with SatraGO-2 demonstrating a significant reduction in eye bulging (proptosis) and improvement in diplopia (double vision), with a favorable safety profile, regardless of TED activity or duration
Enspryng (satralizumab-mwge) represents an important advance for people with TED, offering the first at-home SC treatment option every four weeks during maintenance phase, allowing for greater flexibility in how treatment is administered
Enspryng is an anti-IL-6R mAb using novel recycling antibody technology designed to inhibit IL-6 signaling upstream of autoantibody-driven pathology
TED is a rare autoimmune disease affecting approximately 155 out of every 100,000 people

FDA Approves Genentech’s Enspryng, a First-in-Class IL-6R Inhibitor, as the First and Only At-Home Subcutaneous Treatment Option for Thyroid Eye Disease (TED)

Fri, 16 Oct 2026 01:00:00 -0400

FDA approval based on Phase III SatraGO-1 and -2 studies, with SatraGO-2 demonstrating a significant reduction in eye bulging (proptosis) and improvement in diplopia (double vision), with a favorable safety profile, regardless of TED activity or duration

Enspryng (satralizumab-mwge) represents an important advance for people with TED, offering the first at-home SC treatment option every four weeks during maintenance phase, allowing for greater flexibility in how treatment is administered

Enspryng is an anti-IL-6R mAb using novel recycling antibody technology designed to inhibit IL-6 signaling upstream of autoantibody-driven pathology

TED is a rare autoimmune disease affecting approximately 155 out of every 100,000 people

FDA Approves Genentech’s Enspryng, a First-in-Class IL-6R Inhibitor, as the First and Only At-Home Subcutaneous Treatment Option for Thyroid Eye Disease (TED)

Fri, 16 Oct 2026 01:00:00 -0400

FDA approval based on Phase III SatraGO-1 and -2 studies, with SatraGO-2 demonstrating a significant reduction in eye bulging (proptosis) and improvement in diplopia (double vision), with a favorable safety profile, regardless of TED activity or duration

Enspryng (satralizumab-mwge) represents an important advance for people with TED, offering the first at-home SC treatment option every four weeks during maintenance phase, allowing for greater flexibility in how treatment is administered

Enspryng is an anti-IL-6R mAb using novel recycling antibody technology designed to inhibit IL-6 signaling upstream of autoantibody-driven pathology

TED is a rare autoimmune disease affecting approximately 155 out of every 100,000 people

FDA Approves Genentech’s Enspryng, a First-in-Class IL-6R Inhibitor, as the First and Only At-Home Subcutaneous Treatment Option for Thyroid Eye Disease (TED)

Fri, 16 Oct 2026 01:00:00 -0400

FDA approval based on Phase III SatraGO-1 and -2 studies, with SatraGO-2 demonstrating a significant reduction in eye bulging (proptosis) and improvement in diplopia (double vision), with a favorable safety profile, regardless of TED activity or duration

Enspryng (satralizumab-mwge) represents an important advance for people with TED, offering the first at-home SC treatment option every four weeks during maintenance phase, allowing for greater flexibility in how treatment is administered

Enspryng is an anti-IL-6R mAb using novel recycling antibody technology designed to inhibit IL-6 signaling upstream of autoantibody-driven pathology

TED is a rare autoimmune disease affecting approximately 155 out of every 100,000 people

Genentech Presents New Phase III One-Year Data for Vamikibart in Uveitic Macular Edema (UME), a Serious Cause of Vision Loss

Sat, 10 Oct 2026 17:40:00 -0400

In the MEERKAT and SANDCAT studies, vamikibart demonstrated sustained improvements in vision and reductions in macular thickness in patients with UME at 52 weeks

UME is the leading cause of moderate and severe vision loss in patients with uveitis, posing a significant risk of blindness if left untreated

The FDA has accepted Genentech’s Biologics License Application (BLA), with an approval decision expected by July 2027

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Genentech, a member of the Roche Group (SIX: RO, ROP; OTCQX: RHHBY), announced today new one-year data from the Phase III MEERKAT and SANDCAT studies evaluating investigational vamikibart

Genentech Presents New Phase III One-Year Data for Vamikibart in Uveitic Macular Edema (UME), a Serious Cause of Vision Loss

Sat, 10 Oct 2026 17:40:00 -0400

In the MEERKAT and SANDCAT studies, vamikibart demonstrated sustained improvements in vision and reductions in macular thickness in patients with UME at 52 weeks

UME is the leading cause of moderate and severe vision loss in patients with uveitis, posing a significant risk of blindness if left untreated

The FDA has accepted Genentech’s Biologics License Application (BLA), with an approval decision expected by July 2027

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Genentech, a member of the Roche Group (SIX: RO, ROP; OTCQX: RHHBY), announced today new one-year data from the Phase III MEERKAT and SANDCAT studies evaluating investigational vamikibart

FDA approves Genentech's Tecentriq for stage III colon cancer

Fri, 09 Oct 2026 01:01:50 -0400

The U.S. Food and Drug Administration has approved Genentech's Tecentriq (atezolizumab) in combination with a fluoropyrimidine and oxaliplatin for the adjuvant treatment of stage III deficient DNA mismatch repair (dMMR) colon cancer, according to a statement from Genentech, a member of the Roche Group (SIX: RO, ROP; OTCQX: RHHBY).

The approval covers both Tecentriq and Tecentriq Hybreza (atezolizumab and hyaluronidase-tqjs) and marks the twelfth U.S. indication for the drug. The FDA's decision is based on results from the Phase III ATOMIC study, published in The New England Journal of Medicine, which enrolled 712 patients.

The ATOMIC trial showed that adding Tecentriq to

FDA Approves Genentech’s Tecentriq in Combination With a Fluoropyrimidine and Oxaliplatin for the Adjuvant Treatment of a Certain Type of Stage III Colon Cancer

Fri, 09 Oct 2026 01:00:00 -0400

FDA approval is based on results from the landmark Phase III ATOMIC study, published in The New England Journal of Medicine, which showed Tecentriq plus chemotherapy reduced the risk of disease recurrence or death by 50% compared to chemotherapy alone

First approved adjuvant immunotherapy regimen for stage III dMMR colon cancer, positioning Tecentriq as a new post-surgery standard of care

Nearly 25% of all colon cancers are diagnosed at stage III, and almost one in three patients with stage III colon cancer experience a recurrence within five years

Approval marks the twelfth indication for Tecentriq in the U.S.

SOUTH

FDA Approves Genentech’s Tecentriq in Combination With a Fluoropyrimidine and Oxaliplatin for the Adjuvant Treatment of a Certain Type of Stage III Colon Cancer

Fri, 09 Oct 2026 01:00:00 -0400

FDA approval is based on results from the landmark Phase III ATOMIC study, published in The New England Journal of Medicine, which showed Tecentriq plus chemotherapy reduced the risk of disease recurrence or death by 50% compared to chemotherapy alone

First approved adjuvant immunotherapy regimen for stage III dMMR colon cancer, positioning Tecentriq as a new post-surgery standard of care

Nearly 25% of all colon cancers are diagnosed at stage III, and almost one in three patients with stage III colon cancer experience a recurrence within five years

Approval marks the twelfth indication for Tecentriq in the U.S.

SOUTH

Roche Diagnostics delivers laboratory equipment to support Ebola testing in DRC

Wed, 07 Oct 2026 01:00:00 -0400

Roche Diagnostics has provided two molecular testing instruments to Institut National de Santé Publique (INSP) to support Ebola testing capacity in the DRC.

Roche will preconfigure the instruments and train local laboratory technicians before deploying them to Bunia.

Roche Diagnostics delivers laboratory equipment to support Ebola testing in DRC

Wed, 07 Oct 2026 01:00:00 -0400

Roche Diagnostics has provided two molecular testing instruments to Institut National de Santé Publique (INSP) to support Ebola testing capacity in the DRC.

Roche will preconfigure the instruments and train local laboratory technicians before deploying them to Bunia.

Flatiron Health's Breast Cancer Panoramic Dataset Surpasses One Million Patients, Enabling Real-World Research at Unprecedented Scale

Thu, 01 Oct 2026 09:00:00 -0400

Longitudinal, biomarker-rich real-world data supports precision medicine research across the full breast cancer continuum

NEW YORK--(BUSINESS WIRE)-- Flatiron Health, a leading healthtech company dedicated to improving cancer care and advancing research using real-world data, today announced that its Breast Cancer Panoramic dataset has surpassed one million patients — the largest rigorously curated breast cancer real-world dataset of its kind. This milestone arrives during Breast Cancer Awareness Month, underscoring Flatiron's commitment to transforming patient experiences into evidence that advances care for people living with breast cancer.
The Breast Cancer Panoramic dataset spans the full disease continuum — from early-stage

Flatiron Health's Breast Cancer Panoramic Dataset Surpasses One Million Patients, Enabling Real-World Research at Unprecedented Scale

Thu, 01 Oct 2026 09:00:00 -0400

Longitudinal, biomarker-rich real-world data supports precision medicine research across the full breast cancer continuum

NEW YORK--(BUSINESS WIRE)-- Flatiron Health, a leading healthtech company dedicated to improving cancer care and advancing research using real-world data, today announced that its Breast Cancer Panoramic dataset has surpassed one million patients — the largest rigorously curated breast cancer real-world dataset of its kind. This milestone arrives during Breast Cancer Awareness Month, underscoring Flatiron's commitment to transforming patient experiences into evidence that advances care for people living with breast cancer.
The Breast Cancer Panoramic dataset spans the full disease continuum — from early-stage

Genentech and Breastcancer.org Say It’s “About Damn Time” We Talk About What Happens When Initial Breast Cancer Treatment Ends

Thu, 01 Oct 2026 07:00:00 -0400

More than 225,000 women in the U.S. are expected to be diagnosed with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer this year,1 the most common form of the disease, representing approximately 70% of cases2

For HR+, HER2- early breast cancer patients, completing surgery, chemotherapy or radiation isn’t the finish line — hormone therapy often continues for five years or more to prevent recurrence

Developed alongside patients and leading advocacy groups, About Damn Time spotlights the often overlooked years of treatment, uncertainty, and daily realities that can persist long after initial intensive treatment

SOUTH

Genentech and Breastcancer.org Say It’s “About Damn Time” We Talk About What Happens When Initial Breast Cancer Treatment Ends

Thu, 01 Oct 2026 07:00:00 -0400

More than 225,000 women in the U.S. are expected to be diagnosed with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer this year,1 the most common form of the disease, representing approximately 70% of cases2

For HR+, HER2- early breast cancer patients, completing surgery, chemotherapy or radiation isn’t the finish line — hormone therapy often continues for five years or more to prevent recurrence

Developed alongside patients and leading advocacy groups, About Damn Time spotlights the often overlooked years of treatment, uncertainty, and daily realities that can persist long after initial intensive treatment

SOUTH

Genentech Presents New Data at EURETINA, Highlighting Vabysmo’s Real-World Effectiveness and Safety Across Major Retinal Conditions

Thu, 01 Oct 2026 02:00:00 -0400

New real-world results for Vabysmo in wet AMD, DME and RVO reinforce robust effectiveness and durability across previously untreated and treated eyes, with no new safety signals

Advanced AI-enabled analysis of imaging confirms rapid and meaningful anatomical drying supporting Vabysmo as a standard-of-care therapy in routine clinical care

With more than 5,000 patients enrolled, VOYAGER is the largest, prospective, non-interventional real-world dataset evaluating Vabysmo across diverse clinical practice settings worldwide

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Genentech, a member of the Roche Group (SIX: RO, ROP; OTCQX: RHHBY), announced today new data from the VOYAGER study evaluating the effectiveness, durability

Genentech Presents New Data at EURETINA, Highlighting Vabysmo’s Real-World Effectiveness and Safety Across Major Retinal Conditions

Thu, 01 Oct 2026 02:00:00 -0400

New real-world results for Vabysmo in wet AMD, DME and RVO reinforce robust effectiveness and durability across previously untreated and treated eyes, with no new safety signals

Advanced AI-enabled analysis of imaging confirms rapid and meaningful anatomical drying supporting Vabysmo as a standard-of-care therapy in routine clinical care

With more than 5,000 patients enrolled, VOYAGER is the largest, prospective, non-interventional real-world dataset evaluating Vabysmo across diverse clinical practice settings worldwide

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Genentech, a member of the Roche Group (SIX: RO, ROP; OTCQX: RHHBY), announced today new data from the VOYAGER study evaluating the effectiveness, durability